Basmisanil, also known as RG1662, RO5186582, is a highly selective inverse agonist/negative allosteric modulator of ¦Á5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome. As of August 2015, it is in phase II clinical trials for this indication. Down syndrome (DS) is the most commonly identifiable genetic form of intellectual disability. Individuals with DS have considerable deficits in intellectual functioning (i.e., low intellectual quotient, delayed learning and/or impaired language development) and adaptive behavior.

June 21, 2017

prudect name : Basmisanil, also known as RG1662, RO5186582, is a highly selective inverse agonist/negative allosteric modulator of ¦Á5 subunit-containing GABAA receptors which is under development by Roche for the treatment of cognitive impairment associated with Down syndrome. As of August 2015, it is in phase II clinical trials for this indication. Down syndrome (DS) is the most commonly identifiable genetic form of intellectual disability. Individuals with DS have considerable deficits in intellectual functioning (i.e., low intellectual quotient, delayed learning and/or impaired language development) and adaptive behavior.
Basmisanil

Synonyms: CAS NO: 1159600-41-5Molecular Formula: C₂₁H₂₀FN₃O₅SMolecular Weight: 445.46Purity: 98% minSolubility: DMSOStorage: -20¡æ

GS 7977 References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18505755